X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the expanded collaboration, Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia, which has designed a novel lead series with data showing good potency and selectivity towards the target and differentiated molecular properties.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration December 21, 2023
Details:
Exscientia will use the net proceeds to further explore the requirements for the activation of key aspects of the interferon response of known antiviral effects against influenza and COVID-19.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Open Philanthropy
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Funding December 05, 2023
Details:
Uner the collaboration, Merck will leverage Exscientia’s AI-driven precision drug design and discovery capabilities in oncology and neuroinflammation. Three potential first-in-class or best-in-class targets have been identified as the initial focus of the partnership.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $694.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration September 20, 2023
Details:
GTAEXS617 Exscientia’s precision-designed CDK7 inhibitor, which is investigated for the treatment of advanced solid tumours including head and neck cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), HR+/HER2- breast carcinoma and ovarian cancer.
Lead Product(s): GTAEXS617
Therapeutic Area: Oncology Product Name: GTAEXS617
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GT Apeiron
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
DSP-2342 is a highly-selective bispecific small molecule with potent dual 5-HT2A and 5-HT7 antagonist activity with broad potential in psychiatric disease.
Lead Product(s): DSP-2342
Therapeutic Area: Psychiatry/Psychology Product Name: DSP-2342
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
EXS74539 is a differentiated LSD1 inhibitor with potential in both haematology and oncology. LSD1 demethylates histones which regulates gene expression suppressing differentiation and drive the proliferation and survival of a number of tumour types.
Lead Product(s): EXS74539
Therapeutic Area: Oncology Product Name: EXS74539
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
EXS4318 is a PKC theta inhibitor which plays a critical role in controlling T cell function and is a key driver of several highly prevalent autoimmune diseases. PKC theta inhibitors have potential in inflammatory and immunologic diseases.
Lead Product(s): EXS4318
Therapeutic Area: Immunology Product Name: EXS4318
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2023
Details:
EXS-21546 ('546), Exscientia’s A2A receptor antagonist in combination with anti-PD-1 therapy in patients with immunotherapy relapsed or refractory renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC).
Lead Product(s): EXS-21546
Therapeutic Area: Oncology Product Name: EXS-21546
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evotec SE
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
GTAEXS-617 is novel CDK7 inhibitor designed for high potency, selectivity, bioavailability and safety. CDK7 inhibition combines cell cycle disruption with transcription inhibition, making it an attractive target to overcome common resistance pathways in CDK4/6 inhibition.
Lead Product(s): GTAEXS-617
Therapeutic Area: Oncology Product Name: GTAEXS-617
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: GT Apeiron
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
EXALT-1 was the rst prospective trial to demonstrate signicantly improved outcomes for late-stage haematological cancer patients using an AI-supported precision medicine platform to guide personalised treatment recommendations as compared to physician’s choice of treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
